Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02RKG
|
|||
| Former ID |
DNCL002730
|
|||
| Drug Name |
MORAb-004
|
|||
| Indication | Colorectal cancer [ICD-11: 2B91.Z] | Phase 2 | [1] | |
| Melanoma [ICD-11: 2C30] | Phase 2 | [1] | ||
| Merkel cell carcinoma [ICD-11: 2C34; ICD-10: C44] | Phase 2 | [2] | ||
| Sarcoma [ICD-11: 2A60-2C35] | Phase 2 | [1] | ||
| Company |
Eisai
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Endosialin (CD248) | Target Info | Modulator | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01574716) Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation. (SOURCE). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | A first-in-human phase I study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumors. Clin Cancer Res. 2015 Mar 15;21(6):1281-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.